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OBJECTIVE: The objective of this trial was to determine the levels of inflammatory markers, high-sensitivity
C-reactive protein and fetuin-A pre- and post-levothyroxine treatment in cases of subclinical hypothyroidism.
MATERIALS AND METHODS: A total of 32 patients with a diagnosis of subclinical hypothyroidism and a control
group of 30 healthy individuals were tested for high-sensitivity C-reactive protein and fetuin-A, followed by the
administration of 50 mg of levothyroxine in the patient group for 3 months. During the post-treatment stage,
high-sensitivity C-reactive protein and fetuin-A levels in the patient group were re-assessed and compared with
pre-treatment values.
RESULTS: Pre-treatment levels of both high-sensitivity C-reactive protein and fetuin-A were observed to be
higher in the patient group than in the control group. The decrease in high-sensitivity C-reactive protein levels
during the post-treatment stage was not statistically significant. However, the decrease observed in post-
treatment fetuin-A levels was found to be statistically significant.
CONCLUSION: The decrease in fetuin-A levels in subclinical hypothyroidism cases indicates that levothyroxine
treatment exerts anti-inflammatory and anti-apoptotic effects. Although the decrease in high-sensitivity C-reactive
protein levels was statistically non-significant, it is predicted to reach significance with sustained treatment.
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& INTRODUCTION
Subclinical hypothyroidism (SHO) is a common thyroid
disorder and its prevalence in the adult population has been
reported to be 1-10%. Furthermore, SHO has been found to
be more common in the elderly population (1,2). The
diagnosis of SHO is based on a high serum thyroid-
stimulating hormone (TSH) level and a normal free thyroxin
level. SHO is asymptomatic in general; however, symptoms
suggestive of thyroid hormone deficiency may be present in
30% of patients (3–5). In a cross-sectional study of 2336 cases
of SHO, the symptoms identified were as follows dry skin in
28% of patients, dysmnesia in 24%, deficiency of judgment
in 22%, muscle weakness in 22%, malaise in 18%, muscle
cramps in 17%, cold intolerance in 15%, swelling in eyelids
in 12%, constipation in 8% and hoarseness in 7% (5). These
symptoms were found in 13.7% of the SHO group, in 12.1%
of the euthyroid group and in 16.6% of the hypothyroidism
group, revealing a statistically significant difference. This
finding also showed a correlation between symptoms and
thyroid hormone levels in 16.6% of the hypothyroidism
group. Diverse symptoms of varying severity levels may
develop in cases of SHO, although the disease is theoreti-
cally regarded as asymptomatic. In any case, the presence of
similar symptoms in euthyroid groups and the lack of
detailed, large-scale trials on the treatment response related
to this topic have led to the emergence of diverse treatment
approaches. Depression, amnesia, deficiency in cognitive
functions and various neuromuscular complaints and
disorders have been reported in patients with SHO (6–9).
In addition, abnormal heart function has been shown
related to disordered myocardial contraction and diastolic
dysfunction (10–14).
Fetuin-A (a-Heremans-Schmid glycoprotein) is a circulat-
ing glycoprotein secreted by the liver into the circulation.
Links between fetuin-A and cardiovascular disease, insulin
resistance, diabetes mellitus, metabolic syndrome and non-
alcoholic fatty liver have been reported (15–19).
Our trial was planned to investigate the levels of the
subclinical inflammatory marker high-sensitivity C-reactive
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protein (hs-CRP) and the anti-inflammatory, anti-apoptotic
protein fetuin-A in SHO cases and in a healthy control
group. In addition, the study aimed to show possible
alterations in these inflammatory and anti-inflammatory
markers following levothyroxine treatment in patients with
SHO.
& MATERIALS AND METHODS
A total of 32 patients referred to the Outpatient Clinic of the
Department of Internal Diseases at I˙zmir Bozyaka Education
and Research Hospital for any reason from 2009-2011 were
enrolled in this trial. The selected patients had TSH levels
over 5 mIU/mL and normal FT3 and FT4 levels during
routine laboratory examinations and a diagnosis of SHO. The
exclusion criteria were the administration of treatment for
any condition, surgery on the thyroid or radioactive iodine
treatment and a history of chronic disease; accordingly, the
cases not meeting the designated criteria were enrolled. In
addition, 30 healthy individuals were enrolled on a voluntary
basis to generate a healthy control group. Patients with SHO
were treated with levothyroxine at 50 mg/day for 3 months,
as appropriate based on the indication and venous blood
samples were also collected during the post-treatment stage.
The trial was initiated upon approval of the study protocol by
the Ethical Committee of I˙zmir Bozyaka Education and
Research Hospital.
To determine TSH, FT3, FT4, hs-CRP and fetuin-A levels,
10-mL venous blood samples were obtained from the SHO
cases and healthy controls during the pre- and post-
treatment stages and placed in non-anticoagulant tubes.
The blood samples were kept at room temperature for
approximately 30 minutes until the blood was coagulated
and then centrifuged at 4000 RPM for 5 minutes. Serum
TSH, FT3 and FT4 levels were assessed using the chemilu-
minescence immunoassay method (Immulite 2000 XPi,
Siemens Healthcare Diagnostics Inc., Tarrytown, NY, USA).
To determine hs-CRP and fetuin-A levels, the serum
samples were placed in Eppendorf tubes and kept frozen at
-80 C˚. Following the collection of all samples, the serum
samples were thawed and hs-CRP (DRG Instruments
GmbH, Marburg, Germany) and fetuin-A (BioVendor,
Modrice, Czech Republic) levels were determined using
the enzyme-linked immunosorbent assay (ELISA) method
according to the manufacturers’ protocols.
Statistical analysis
All statistical analyses were performed using the
Statistical Package for the Social Sciences (SPSS; version
11.0 for Windows, Chicago, IL, USA). The data are
expressed as the mean ¡ standard deviation (SD). A two-
sided p-value,0.05 was considered statistically significant.
A nonparametric Mann-Whitney U test was used to
compare the variables between patients and controls and
the Wilcoxon signed-rank test was used to compare the
variables between treated and untreated SHO patients.
& RESULTS
The pre- and post-treatment FT3, FT4, TSH, hs-CRP and
fetuin-A levels of the patients with SHO and the healthy
control group are shown in Table 1. The mean ages of the 32
SHO cases and the 30 healthy controls were determined to
be similar.
There was a significant difference in hs-CRP, fetuin-A,
FT3 and TSH levels between pretreatment of SHO group
and control group (Figures 1, 2 and 3). After treatment,
fetuin-A levels were significantly decreased in the SHO
patients. However, no statistically significant difference was
observed in hs-CRP levels with treatment. The decrease
observed in hs-CRP levels during the post-treatment stage
was not statistically significant (Figure 1). In contrast, the
decrease observed in post-treatment fetuin-A levels was
found to be statistically significant (Figure 2). Comparison
of pre- and post-treatment TSH values revealed a significant
decrease in post-treatment TSH levels (Figure 3).
Comparison of pre- and post-treatment FT3 and FT4 values
did not reveal a significant difference.
Table 1 - Demographic and clinical parameters in SHO patients and controls.
Subclinical hypothyroidism
(before treatment) (n = 32)
Subclinical hypothyroidism
(after treatment) (n = 24) Control group (n=30)
Age (years) 44.28¡10.13 43.50¡10.59 40.17¡8.29
hs-CRP (mg/L) 5.70¡5.85 4.85¡4.01 2.06¡3.30
Fetuin-A (mg/mL) 410.40¡69.59 329.98¡166.71 350.30¡210.87
FT3 (pg/mL) 3.02¡0.43 2.84¡0.45 2.69¡0.38
FT4 (ng/dL) 0.82¡0.13 0.83¡0.17 0.81¡0.11
TSH (mIU/mL) 6.57¡2.53 4.64¡2.99 2.11¡1.26
The results are given as the mean ¡ SD. A p-value of ,0.05 was considered significant.
Figure 1 - Comparisons of hs-CRP level in SHO group, SHO
patients after treatment and healthy controls. (*p,0.001)
(**p=0.440)
Abbreviation: SHO, subclinical hypothyroidism.
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& DISCUSSION
SHO is a common disease affecting 3 million individuals
in the United Kingdom and 15 million individuals in the
USA. The importance of this disease is based on data
indicating its potential to induce an atherogenic lipid
profile and endothelial dysfunction. In addition, co-morbid-
ity of SHO and cardiovascular disease and an increase in
mortality rates have been reported in several studies.
Considering the serious outcomes of such a common
disease, the importance of trials that have been and will
be performed is increasing.
The acute-phase reactant hs-CRP is known to be an
exceptionally sensitive and non-specific marker for inflam-
mation, tissue damage and infection. Elevated hs-CRP levels
indicate the presence and severity of inflammation (14). In
current clinical practice, serum hs-CRP measurements are
used to determine risks and to monitor treatment effective-
ness. Hs-CRP is a cardiovascular risk marker, which has
been regarded as significant in recent years following the
recognition of atherosclerosis as an inflammatory disease.
The correlation of SHO and prominent hypothyroidism
with coronary heart disease in particular has been shown in
a number of trials. However, although hypothyroidism and
atherosclerosis are closely related, the correlation between
thyroid function tests and hs-CRP levels has varied among
different trials.
Currently, hs-CRP is regarded as a predictive marker for
myocardial infarction, stroke, peripheral artery disease and
sudden cardiac death among individuals with no cardio-
vascular disease and as a predictive marker for recurrent
attacks and mortality in cases of metabolic syndrome (20).
Based on previous trials, in terms of cardiovascular risk,
individuals with hs-CRP levels ,1 mg/L are regarded as
low risk; individuals with levels between 1-3 mg/L, as
moderate risk; and individuals with levels.3 mg/L, as high
risk (21). Recent data suggest that CRP has a direct role in
atherogenesis. CRP induces the expression of intracellular
adhesion molecule-1 (ICAM-1) and vascular adhesion
molecule-1 (VCAM-1) in endothelial cells and mediates
monocyte chemoattractant protein (MCP-1) induction and
the phagocytosis of LDL by macrophages. CRP induces the
synthesis of tissue factor, a strongly pro-coagulant sub-
stance, in monocytes and may bind to activated complement
(22). As a result of all of these actions, CRP plays a role in
endothelial dysfunction (23). In many trials conducted in
diverse groups, a strong correlation was found between
CRP levels and cardiovascular disease (24). In one trial
performed in a patient group with a history of myocardial
infarction, stroke and venous thrombosis and in a control
group with no history of the indicated diseases, the patients
were followed for 14 years and a group with trough hs-CRP
values (,0.55 mg/L) was compared with a group with
maximum values (.2.11 mg/L). The results indicated a 2-
fold increase in stroke risk, a 3-fold increase in myocardial
infarction and a 4-fold increase in symptomatic peripheral
vascular disease in the group with maximum values (25).
The role of hs-CRP in coronary heart disease was shown in
another trial. Basal hs-CRP concentrations were measured in
a healthy middle-aged group that was then followed for 8
years and an increase in the SD of hs-CRP levels was shown
to increase the risk of coronary heart disease by 50% (26).
In the current trial, levothyroxine was administered in
cases of SHO for 3 months and differences in hs-CRP values
following treatment (if any) were assessed. Although a
decrease was observed in these values, it did not reach a
statistically significant level (p = 0.440). However, statisti-
cally significant decreases may be obtained by increasing
the dose of levothyroxine used in treatment, which is
expected to further decrease TSH values and by prolonging
the treatment duration.
Fetuin-A is a protein with anti-inflammatory and anti-
apoptotic effects. Mice with fetuin gene ablation are
congenitally prone to calcifications, leading to fatal calcifica-
tions in the kidneys, testes, skin, heart and vessels (27).
Fetuin-A may inhibit the activity of the insulin receptor
tyrosine kinase, which causes insulin resistance. This
glycoprotein also regulates bone development and re-
formation by antagonizing the activity of TGF-b (28). The
Figure 2 - Comparisons of fetuin A level in SHO group, SHO
patients after treatment and healthy controls. (*p=0.019)
(**p=0.012)
Abbreviation: SHO, subclinical hypothyroidism.
Figure 3 - Comparison of pre-treatment and post-treatment
TSH, FT3 and FT4 values of patients with Subclinical
Hypothyroidism and healthy control group.
Abbreviation: SHO, subclinical hypothyroidism.
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normal serum concentration is 0.5-1 g/L and the levels
decrease during inflammation. In addition, an inverse
correlation has been reported between serum fetuin-A and
CRP (29). Low fetuin-A levels among hemodialysis patients
are associated with a high risk of cardiovascular disease and
increased mortality. The main activity of fetuin-A is the
inhibition of Ca-P accumulation. In vitro, this protein has
been shown to inhibit the formation of apatites in osteoblast
cultures. In addition, fetuin-A displays anti-inflammatory
activity by regulating the phagocytosis of apoptotic particles
by macrophages (30,31). In one trial, fetuin-A was reported
to play a role in the inhibition of calcification in vascular
smooth muscle cells (32).
In a trial conducted in adults, a comparison of the fetuin-
A levels of healthy controls and a patient group comprising
end-stage renal failure and dialysis cases revealed signifi-
cantly low levels in both groups (33). In another trial
conducted in 141 healthy individuals, serum fetuin-A levels
and sclerosis of the vessel wall in the carotid artery were
shown to be correlated and this correlation was indicated to
be significant and independent of other well-known
atherogenic factors (34).
Accordingly, in the present study, a statistically signifi-
cant decrease was found in fetuin-A levels following 3
months of levothyroxine treatment compared with pre-
treated values in cases of SHO. Considering that the etiology
of the majority of SHO cases is thyroiditis, it is evident that
even short-term levothyroxine treatment exerts anti-inflam-
matory and anti-apoptotic effects in these patients. Hence,
even in cases without any alterations in FT3 and FT4 levels,
thyroid replacement treatment may decrease the need for
the management of future cardiovascular problems that
would otherwise be expected to develop based on endothe-
lial dysfunction and an atherogenic lipid profile.
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